Maze Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Jason Coloma, Ph.D, president and chief executive officer of Maze, will present a company overview at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 1:30 p.m. ET.
About Maze Therapeutics
Maze Therapeutics is focused on translating genetic insights into new precision medicines for patients with rare diseases and mechanistically defined subsets of common diseases. Maze has developed the MAZE COMPASStm platform, a proprietary, purpose-built platform that combines human genetic data, functional genomic tools and data science technology to map novel connections between known genes and their influence on susceptibility, timing of onset and rate of disease progression. Using COMPASS, Maze is building a broad portfolio, including wholly owned programs targeting Pompe disease, chronic kidney disease and amyotrophic lateral sclerosis, as well as partnered programs in cardiovascular and ophthalmic diseases. Maze is based in South San Francisco. For more information, please visit mazetx.com, or follow us on LinkedIn.
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...
DelveInsight's Urine Output Monitoring Systems Market Insights report provides the current and forecast market analysis, individual leading urine output monitoring systems companies' market...
Enghouse Video, a global leader in cutting-edge video technology solutions, today announced its partnership with SONIFI Health, enhancing virtual care in hospital settings.
SONIFI Health is a leading U.S. healthcare technology company based in Sioux...
A record 3,618 graduating students and physicians matched to residency training programs in Canada in this year's R-1 Main Residency Match (R-1 match), the Canadian Resident Matching Service (CaRMS) announced today....
Hondros College of Nursing (HCN) will introduce a new Medical Assisting program at its six Ohio campuses in 2024 to meet the growing need for medical assistants in a variety of settings.
According to the U.S. Bureau of Labor Statistics (BLS),...
Halozyme Therapeutics, Inc. ("Halozyme") today announced the election of Mahesh Krishnan, M.D. to its Board of Directors. Dr. Krishnan has more than 20 years of experience in healthcare, biotechnology and health services.
"Mahesh is a dynamic and...
